Evaluation of biotechnology products

Pharmacotherapy

Volumn 16, Issue 4, 1996, Pages 527-536

  Tami, Joseph ^a   Evens, Ronald P ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN3 INTERFERON; ALTEPLASE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BETA1 INTERFERON; BETA1A INTERFERON; BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR 8; DAUNORUBICIN; DORNASE ALFA; DOXORUBICIN; HEPATITIS B VACCINE; HUMAN GROWTH HORMONE; HUMAN INSULIN; IMIGLUCERASE; INSULIN; OKT 3; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; SOMATREM;

BIOTECHNOLOGY; DRUG COST; DRUG STABILITY; GLYCOSYLATION; HEALTH CARE COST; HEALTH CARE SYSTEM; PATIENT CARE; PHARMACY; REIMBURSEMENT; REVIEW;

BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; DRUG MONITORING; DRUG STABILITY; DRUG STORAGE; EVALUATION STUDIES; HUMANS;

EID: 0029847253     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Pharmaceutical Manufacturer's Association. 1995 survey report: biotechnology medicines in development. Washington, DC: Author, 1995.
2. Anonymous. Use of approved drugs for unlabeled indications. FDA Drug Bull 1982;12:4-5.
3. Huber SL. Reimbursement issues with interferon therapies. Semin Oncol 1988;15(5 suppl):54-7.
4. Crawford J, Ozer H, Stoller R, et al. Reduction by G-CSF of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
5. Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant human granulocyte-macrophage colony stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988;72:834-6.
6. Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther 1993;15(1):19-29.
7. Gribben JG, Devereux S, Thomas NS, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990;335(8687):434-7.
8. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991;163:882-5.
9. Freund M, von Wussow P, Diedrich H, et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 1989;72(3):350-6.
10. Steiss RG, Smith JW II, Urba WJ, et al. Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988;318(22):1409-13.
11. Niaudet P, Jean G, Broyer M, Chatenoud L. Anti-OKT3 response following prophylactic treatment in pediatric kidney transplant recipients. Pediatr Nephrol 1993;7(3):263-7.
12. Norman DJ, Chatenoud L, Cohen D, Goldman M, Shield CF III. Consensus statement regarding OKT-3 induced cytokine release and human antimouse antibodies. Transplant Proc 1993;25(2 suppl 1):89-92.
13. Jolliffe LK. Humanized antibodies: enhancing therapeutic utility through antibody engineering. Int Rev Immunol 1993;10:241-50
14. Crowe JE Jr, Murphy BR, Chanock RM, et al. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA 1994;91:1386-90.
15. Burton DR. Human and mouse monoclonal antibodies by repertoire cloning. Trends Biotechnol 1991;9(5):169-75.
16. Petros WP. Pharmacokinetics and administration of colony-stimulating factors. Pharmacotherapy 1992;12(2 Pt 2):32S-8.
17. Amgen Inc. Neupogen (filgrastim) package insert. Thousand Oaks, CA; 1994.
18. Immunex Corporation. Leukine (sargramostim) package insert. Seattle, WA; 1992.
19. Santell JP. Projecting future drug expenditures-1995. Am J Hosp Pharm 1995;52:151-63.
20. Glaspy JA, Jakway J. Cost considerations in therapy with myeloid growth factors. Am J Hosp Pharm 1993;50(7):S19-26.
21. Huber SL. Strategic management of biotechnology agents. Am J Hosp Pharm 1993;50:S31-3.
22. Nemunaitis J, Rabinowe J, Singer J, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-8.
23. Evans R, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990;263(6):825-30.
24. Reeder CE. Economic outcomes and contemporary pharmacy practice. Am Pharm 1993;NS33(12 suppl):33-6.